ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/MEK
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/MEK
12
trial(s) found.
NCT06804824
Advanced
Phase 1
Recruiting
A Phase 1/1b, Open-Label, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-159642, a RAS-PI3Kα Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors (
VVD-159642-01
)
HRAS G12C inhibitor
HRAS inhibitor
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
KRAS G12C inhibitor
KRAS inhibitor
MEK inhibitor
NRAS G12C inhibitor
NRAS inhibitor
Sotorasib
Trametinib
cancer therapy
cancer therapy,HRAS G12C-targeting
cancer therapy,KRAS-targeting
cancer therapy,KRAS G12C-targeting
cancer therapy,MEK-targeting
cancer therapy,NRAS G12C-targeting
+ MEK inhibitor
Solid tumour
WA
6009 - Nedlands - Linear Clinical Research
NCT06346067
Advanced
Phase 3
Recruiting
A Randomized, Open-label Phase III Study in Patients With Previously Treated Unresectable or Metastatic NRAS Mutant Cutaneous Melanoma Comparing the Combination of Naporafenib + Trametinib to Physician's Choice of Therapy (Dacarbazine, Temozolomide or Trametinib Monotherapy) With a Dose Optimization lead-in [SEACRAFT-2] (
ERAS-254-02
)
MEK inhibitor
RAF dimer inhibitor
alkylating agent
Melanoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Tasman Oncology
WA
6009 - Nedlands - Hollywood Private Hospital
NCT06326411
Advanced
Phase 1
Recruiting
A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue
NST-628
Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors
pan-RAF/MEK glue
Glioma
Melanoma
NOT Melanoma
Non-small cell lung cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT06072781
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301) (
RAMP-301
)
FAK inhibitor
RAF/MEK clamp
Low-grade serous ovarian cancer
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05907304
Advanced
Phase 1
Recruiting
An Open-label Study to Assess the Safety and Efficacy of Naporafenib (ERAS-254) Administered With Trametinib in Previously Treated Patients With Locally Advanced Unresectable or Metastatic Solid Tumor Malignancies With RAS Q61X Mutations (
SEACRAFT-1
)
MEK inhibitor
RAF dimer inhibitor
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6009 - Nedlands - Linear Clinical Research
NCT05203172
Advanced
Phase 4
Recruiting
ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES (
C4221026
)
BRAF V600 inhibitor
MEK inhibitor
Solid tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05182931
Advanced
Phase 2
Recruiting
A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (
I-FIRST
Study)
BRAF V600 inhibitor
BRAF inhibitor
Dabrafenib
MEK inhibitor
RAF inhibitor
Trametinib
cancer therapy
cancer therapy,BRAF-targeting
cancer therapy,BRAF V600-targeting
cancer therapy,MEK-targeting
cancer therapy,RAF-targeting
+ MEK inhibitor
NOT Anaplastic thyroid cancer
Thyroid cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3181 - Prahran - The Alfred Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04185883
Advanced
Phase 1
Recruiting
A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
+ MEK inhibitor
Sarcoma
Solid tumour
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (TERMINATED)
NCT03947385
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (
IDE196-001
)
PKC inhibitor
+ MEK inhibitor
Colorectal cancer
Cutaneous melanoma
Solid tumour
Uveal melanoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
NCT02645149
Advanced
Phase 2
Recruiting
Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (
MatchMel
)
ALK/ROS1/IGF1R inhibitor
ALK inhibitor
ALK inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Ceritinib
IGF1R inhibitor
MEK inhibitor
ROS1 inhibitor
Ribociclib
Trametinib
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,IGF1R-targeting
cancer therapy,MEK-targeting
cancer therapy,ROS1-targeting
+ MEK inhibitor
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
NCT05580770
Advanced
Phase 1 / Phase 2
Terminated
A Phase 1/2a Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Mirdametinib in Combination With BGB-3245 in Patients With Advanced Solid Tumors (
MEKRAF-AST-101
)
MEK inhibitor
RAF dimer inhibitor
Melanoma
Non-small cell lung cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05270044
Curative
Phase 3
Active not recruiting
Adjuvant Encorafenib & Binimetinib vs. Placebo in Fully Resected Stage IIB/C BRAF V600E/K Mutated Melanoma: a Randomized Triple-blind Phase III Study in Collaboration With the EORTC Melanoma Group (
COLUMBUS-AD
)
BRAF V600 inhibitor
MEK inhibitor
placebo
Melanoma
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3181 - Prahran - The Alfred Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6009 - Nedlands - Hollywood Private Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (10)
Terminated (1)
Active not recruiting (1)
Recruitment Country and State
NSW (10)
VIC (8)
WA (7)
QLD (6)
SA (5)
NZ (1)
Phase
Phase 1 (4)
Phase 1 / Phase 2 (2)
Phase 2 (2)
Phase 3 (3)
Phase 4 (1)
Trial Type
Advanced (11)
Curative (1)
Cancer Therapy Class
MEK
100%
BRAF
67%
RAF
67%
BRAF V600
25%
CDK4
25%
CDK6
25%
HRAS G12C
17%
KRAS
17%
KRAS G12C
17%
NRAS G12C
17%
CRAF
17%
pan-RAF
17%
EGFR
17%
ALK
17%
ROS1
17%
FAK
8%
oestrogen axis
8%
ERBB2
8%
PD-1
8%
PD-1/PD-L1
8%
PD-L1
8%
SHP2
8%
VEGF
8%
mTOR
8%
mTORC1
8%
MET
8%
PKC
8%
IGF1R
8%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (5)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (3)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (3)
6009 - Nedlands - Linear Clinical Research (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
6009 - Nedlands - Hollywood Private Hospital (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
3181 - Prahran - The Alfred Hospital (2)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (2)
3004 - Melbourne, Southbank - Alfred Health (1)
4215 - Southport - Tasman Oncology (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
2031 - Randwick - Prince of Wales Hospital (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
2109 - North Ryde - Macquarie University Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (1)
Cancer Type
Cancer
Solid tumour
Melanoma
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Central nervous system cancer
Glioma
Neurological cancer
Epithelial Ovarian Cancer
Gynaecological cancer
Low-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian cancer
Ovarian serous carcinoma
Endocrine gland cancer
Thyroid cancer
Sarcoma
Colorectal cancer
Cutaneous melanoma
Gastrointestinal cancer
Lower gastrointestinal cancer
Skin cancer
Uveal melanoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy